Install
Your go-to source for the latest news in health, science and medicine. Sign up for STAT+ for exclusive analysis of biotech, pharma, and the life sciences.
- 204articles · 30d
- 1+ day agolatest article
- Aug 14, 2026earliest in window
- 94%with images
- 247avg words
- Medical 149
- Health & Wellness 139
- Health 101
- Science & Technology 46
- Business & Industrial 36
- Economy, Business & Finance 21
- Politics 20
- Politics2 18
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Why two promising heart drugs flopped and what's next
3+ day, 4+ hour ago (222+ words) By Adam Feuerstein, Elaine Chen, and Allison DeAngelis On this week’s episode of “The Readout LOUD”: The pharma industry invested billions of dollars to develop drugs heralded as the next era in the treatment of heart disease — but why did…...
Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field
2+ day, 21+ hour ago (159+ words) The back-to-back failures of cardiovascular drugs from Novartis and Novo Nordisk made headlines earlier this month. They could also have a chilling effect across the industry. Just before Labor Day, Novartis reported that its cardiac therapy, pelacarsen, failed in a…...
The gifts from pharma companies that keep on giving
3+ day, 4+ hour ago (218+ words) Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for more than three decades. His stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is…...
Pharmalittle: We're reading about an AstraZeneca COPD win, the FDA filling key jobs, and more
4+ day, 8+ hour ago (167+ words) Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter. FDA names acting heads of drug and vaccine…...
Pharmalittle: We're reading about another Novartis trial failure, a Novo Nordisk setback, and more
5+ day, 8+ hour ago (369+ words) Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for more than three decades. His stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation and legislation. He is…...
We're reading about an Ultragenyx failure, RevMed for lung cancer, and more
1+ week, 3+ day ago (252+ words) STAT is a media company focused on finding and telling compelling stories about health, medicine, and scientific discovery. We produce daily news, investigative articles, and narrative projects in addition to multimedia features, podcasts, and opinion pieces. We tell our stories…...
Pharmalittle: We're reading about a Huntington's gene therapy, Novo's challenges, and more
1+ week, 4+ day ago (172+ words) STAT Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more New White House drug pricing deals might not amount to much, at least not immediately Andrew covers the biopharma industry, scientific research, and public health across the…...
Five burning questions on Trump’s latest deals with drugmakers
1+ week, 5+ day ago (317+ words) By Daniel Payne, Elaine Chen, and John Wilkerson The Trump administration on Monday announced a second group of pharmaceutical companies had pledged to lower drug prices to levels comparable to those in other nations. Here are some of the biggest…...
Novartis gets multiple sclerosis win with BTK inhibitor
1+ week, 5+ day ago (270+ words) By Elaine Chen and Helen Branswell Good morning. I know this week probably feels extra long as we approach Labor Day weekend, but we will get through it together. President Trump yesterday announced that his administration has made deals with…...
Pharmalittle: We're reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more
1+ week, 5+ day ago (258+ words) STAT Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more President Trump has announced the next round of pricing deals with drugmakers Andrew covers the biopharma industry, scientific research, and public health across…...